Difference between revisions of "Nortriptyline-venlafaxine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = venlafaxine
 
| to = venlafaxine
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of nortriptyline to a maximum of 100 mg/day.
+
{{downNortriptyline}}
* '''Day 1:''' reduce dosage of nortriptyline to 50 mg/day.
 
* '''Day 3:''' reduce dosage of nortriptyline to 25 mg/day.
 
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start administration of venlafaxine in a normal dosage of 75 mg/day.
 
* '''Day 1:''' simultaneously start administration of venlafaxine in a normal dosage of 75 mg/day.
Line 11: Line 9:
 
| info =  
 
| info =  
 
* Occurrence of serotonin syndrome is theoretically (not very likely) possible, so caution is necessary.
 
* Occurrence of serotonin syndrome is theoretically (not very likely) possible, so caution is necessary.
{{review}}
 
 
}}
 
}}

Revision as of 14:21, 2 November 2015

Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from nortriptyline to venlafaxine.[1] [2]

Nietinrijdenbord.png Stop nortriptyline
  • Day 1: reduce dosage to 50%.
  • Day 8: stop
Eenrichtingbord.png Start venlafaxine
  • Day 1: simultaneously start administration of venlafaxine in a normal dosage of 75 mg/day.
  • Day 8: stop administration of nortriptyline and continue administration of venlafaxine.
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically (not very likely) possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.